Genmab — Maj 2015
-
Hvis Elo er næsten ubetydelig i kapløbet sammen med SAR ligner det soloridt i den brede label som "first and best in class". Det alene bør udløse nye kurstargets. Om ikke andet så efter ASCO. Det bliver ekstremt spændende i dagene op til og efter.
-
JKY, Der var engang
http://finans.tv2.dk/nyheder/article.php/id-22747526 GS= Genmabs største fan!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind